VitalTrace has had the pleasure of participating in iPREP WA's Industry and PhD Research and Engagement Program. We were fortunate to work with our very own “Dream Team”; Alvin Lee, Saman Akbar Zadeh and Georgios Mavropalias, bringing their expertise in signal processing, data science and biomedical science respectively.
No items found.
No items found.
VitalTrace receives $4M from the WA government to establish a new manufacturing facility
VitalTrace is proud to announce it has received support from the Cook government, under the Investment Attraction Fund (IAF) which supports WA advanced manufacturing projects as part of an effort to diversify the Western Australia economy.
August 1, 2023
•
3 min read
VitalTrace is proud to announce it has received support from the Cook government, under the Investment Attraction Fund (IAF) which supports WA advanced manufacturing projects as part of an effort to diversify the Western Australia economy.
The IAF is intended to enable new investment into a range of industries, facilitating a more targeted and coordinated approach to investment attraction supporting the WA Government's economic diversification framework, Diversify WA.
Roger Cook, Premier of Western Australia said “Backing local companies to manufacture here in WA, to value-add, and to take on the world in developing high-tech products for the future.”
The dedicated and growing team at VitalTrace hopes to make good on Premier Cook’s support and create a nation first continuous lactate biosensor manufacturing facility.
No items found.
VitalTrace presents pre-clinical data at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting
Prof. Jonathan Morris, Chief Medical Officer, presents VitalTrace’s pre-clinical data in the highly regarded Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting in Denver, Colorado.
January 28, 2025
•
3 min read
From Prof. Jonathan Morris, VitalTrace - Chief Medical Officer
I had the wonderful opportunity to present VitalTrace’s pre-clinical data in the highly regarded Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting in Denver, Colorado. This is the premier pregnancy meeting in USA. Our abstract was one of the 104 selected for presentation out of more than 2,000 submitted speaking to the significance and magnitude of the accomplishments we have achieved.
SMFM was a great opportunity to connect with obstetricians allowing VitalTrace to build invaluable relationships with leading practitioners and forming alliances to prepare the company for future activity in the United States and beyond. There was very strong interest in DelivAssure from leaders in Boston, Washington, Texas, East Virginia, New York and Philadelphia amongst others.
Some particularly notable feedback:
From Dr Emily Reiff (Brigham and Women’s Hospital, Harvard Medical School),
“I was fascinated by your study of real-time fetal lactate monitoring and think that innovation like this is what is needed for effective intrapartum management.”
From Dr Justin Lappen (Cleveland Clinic),
“The whole team thought that DelivAssure would assist with Class II CTG dilemmas.”
It was reinvigorating to see such strong support for continuous lactate monitoring and reinforces our confidence to launch DelivAssure in the United States.
No items found.
VitalTrace awarded $656,666 for the Clinical translation of a novel continuous lactate biosensor for fetal monitoring
VitalTrace was founded to improve the safety for mothers and babies during childbirth - babies being some of our youngest and most vulnerable patients.
September 30, 2023
•
3 min read
VitalTrace was founded to improve the safety for mothers and babies during childbirth - babies being some of our youngest and most vulnerable patients. We are passionate about eliminating the unnecessary health, psychological and economic burdens from inaccurate childbirth monitoring.
This project will progress development and clinical testing of a continuous lactate sensor, with the potential to revolutionise fetal monitoring during labour globally.
Current fetal monitoring technology is inaccurate, subjective and creates difficulties for clinicians leading to complications for mothers and babies. VitalTrace is developing DelivAssureTM, a breakthrough technology designed to continuously monitor clinically validated biomarkers to reduce fetal morbidities and wirelessly transmit readings to an associated display monitor.
The funding awarded through the Clinical Translation and Commercialisation Medtech grant, will help design and run VitalTrace's first clinical trial, testing DelivAssureTM, a novel continuous lactate biosensor, which has already received Breakthrough Device designation from the US FDA.